MSJ917925_supplemental_figure_1 – Supplemental material for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP)
Helmut Butzkueven
Maria Trojano
Ludwig Kappos
Tim Spelman
Heinz Wiendl
Karen Rosales
Ray Su
Stephanie Licata
Pei-Ran Ho
Nolan Campbell
10.25384/SAGE.12311060.v1
https://sage.figshare.com/articles/journal_contribution/MSJ917925_supplemental_figure_1_Supplemental_material_for_Clinical_outcomes_in_patients_who_discontinue_natalizumab_therapy_after_2_years_in_the_Tysabri_sup_sup_Observational_Program_TOP_/12311060
<p>Supplemental material, MSJ917925_supplemental_figure_1 for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP) by Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Karen Rosales, Ray Su, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Multiple Sclerosis Journal</p>
2020-05-15 12:10:38
Discontinuation
disease-modifying therapy
multiple sclerosis
natalizumab
observational study
relapse